AU2022416156B2 — Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor
Assigned to Loxo Oncology Inc · Expires 2025-08-21 · 1y expired
What this patent protects
Provided herein are methods of preparing crystalline, selpercatinib Form A, which contains little to none of the thermodynamically more stable, crystalline selpercatinib Form B. Selpercatinib is useful in the treatment and prevention of diseases which can be treated with a RET ki…
USPTO Abstract
Provided herein are methods of preparing crystalline, selpercatinib Form A, which contains little to none of the thermodynamically more stable, crystalline selpercatinib Form B. Selpercatinib is useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.